Apnimed, Inc.

APMD

Healthcare Biotechnology

Apnimed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, up 380.1% from fiscal 2024.

15.10 0.94 +6.64%
Market cap
$628.6M
P/E
0.8×
Fwd P/E
4.3×
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
0.0×
Dividend safety
n/a
Dec '25 Dec '24
P/E ratio
1.27 1.27
P/S ratio
1.02 1.02
Altman Z″-Score (non-manufacturers)
(29.54) (13.94)
P/FCF ratio
0.00 0.00
Beneish M-Score
0.00 —
P/Operating CF
(6.62) (6.62)
P/B ratio
0.00 0.00
EV/Sales
0.23 0.23
EV/EBITDA
1.15 1.15
EV/FCF
(0.32) (0.32)
Current Ratio
0.41 1.73
Net Debt/EBITDA
0.02 0.60
Debt/Equity
(0.11) 0.00
ROE
41.26% 0.00%
ROA
(140.79%) 0.00%
ROIC
0.00% 0.00%
Return on Tangible Assets
194.95% (359.28%)
Average Days of Receivables
9.10 50.80
Earnings Yield
78.94% 78.94%
Free Cash Flow Yield
(69.83%) (69.83%)
Free Cash Flow per Share
(16.34) (23.25)
Book value per Share
(78.27) (52.41)
Free Cash Flow
(77.83) (110.28)
EV/EBIT
1.15 1.15
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026